Preferred Label : Anti-CD47/CD20 Bispecific Antibody IMM0306;
NCIt synonyms : Anti-CD20/CD47 mAb-Trap IMM0306; Anti-CD20/CD47 Antibody Receptor Recombinant Protein IMM0306;
NCIt related terms : IMM-0306;
NCIt definition : A bispecific antibody directed against both the B-cell-specific membrane protein and
tumor-associated antigen (TAA) CD20, and the human cell surface antigen CD47, with
potential immunostimulating, phagocytosis-inducing and antineoplastic activities.
Upon administration of anti-CD47/CD20 bispecific antibody IMM0306, the anti-CD20 moiety
selectively targets and binds to CD20 on CD20-positive B-cells, thereby improving
the binding of the anti-CD47 moiety to the CD20-positive malignant B-cells. The CD47
binding by IMM0306 blocks the interaction of CD47 with signal regulatory protein alpha
(SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs),
which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated
inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the
binding of calreticulin (CRT), which is specifically expressed on the surface of tumor
cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed
on macrophages, which results in macrophage activation and the specific phagocytosis
of the CD20/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates
an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD20/CD47-expressing
tumor cells. In addition, IMM0306 may induce an anti-tumor activity through the induction
of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated
protein (IAP), is widely expressed on normal, healthy cells, such as red blood cells
and platelets, and overexpressed on the surface of a variety of cancer cells. Expression
of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage
activation and protects cancer cells from phagocytosis, which allows cancer cells
to proliferate. CD20 is a membrane antigen that is overexpressed in B-cell malignancies.
By co-targeting CD47 and CD20, IMM0306 has the potential to overcome the limitations
of existing CD47-targeted therapies by possibly avoiding the side effects caused by
binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated
phagocytosis.;
UNII : HFR7WU5YK7;
Molecule name : IMM 0306; IMM-0306;
NCI Metathesaurus CUI : CL1662429;
Origin ID : C179653;
UMLS CUI : C5555844;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
